Huang C, Ren S, Chen Y, Liu A, Wu Q, Jiang T, et al. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Sci Adv. 2023;9:eade4186 pubmed publisher

Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33:341-354 pubmed publisher

Liu C, Xiao H, Cui L, Fang L, Han S, Ruan Y, et al. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer. Front Immunol. 2022;13:1039631 pubmed publisher

Jarosch S, K xf6 hlen J, Wagner S, D Ippolito E, Busch D. ChipCytometry for multiplexed detection of protein and mRNA markers on human FFPE tissue samples. STAR Protoc. 2022;3:101374 pubmed publisher

Zhang T, Zhao Y, Cheung W, Gan Y, Huang L, Li M, et al. Serial changes in two immune checkpoint receptors and ligands, Tim-3/Gal-9 and PD-1/PD-L1 in peripheral blood prior to miscarriage: Comparison with pregnancies resulting in a live birth. Am J Reprod Immunol. 2022;87:e13524 pubmed publisher

Zheng W, Lai G, Lin Q, Issah M, Fu H, Shen J. A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint. Front Cell Dev Biol. 2021;9:735855 pubmed publisher

Zhao J, Schank M, Wang L, Li Z, Nguyen L, Dang X, et al. Mitochondrial Functions Are Compromised in CD4 T Cells From ART-Controlled PLHIV. Front Immunol. 2021;12:658420 pubmed publisher

Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, et al. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics. 2021;11:4957-4974 pubmed publisher

Lin G, Zhang Y, Yu L, Wu D. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia. Mol Med Rep. 2021;23: pubmed publisher

Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29:1794-1807 pubmed publisher

Wang J, Hasan F, Frey A, Li H, Park J, Pan K, et al. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020;8:794-805 pubmed publisher